Brief: Roche To Collaborate With Nurix Therapeutics On BTK Degrader Bexobrutideg
BRIEF-Roche To Collaborate With Nurix Therapeutics On BTK Degrader Bexobrutideg June 8 (Reuters) - ROCHE HOLDING AG ROPC.S:
ANNOUNCES GLOBAL COLLABORATION WITH NURIX THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALISE POTENTIAL BEST-IN-CLASS BTK DEGRADER BEXOBRUTIDEG ACROSS MALIGNANT HAEMATOLOGY, IMMUNOLOGY AND NEUROLOGY
NURIX TO RECEIVE $700 MILLION UPFRONT; DEAL VALUE UP TO $2.3 BILLION
NURIX WILL RECEIVE AN UPFRONT CASH PAYMENT OF USD 700 MILLION
DEVELOPMENT COSTS SHARED 40% NURIX, 60% ROCHE; U.S. PROFITS AND LOSSES SPLIT EQUALLY
PARTIES WILL EQUALLY SPLIT PROFITS AND LOSSES FROM U.S. COMMERCIALISATION
DEAL EXPECTED TO CLOSE IN Q3 2026, SUBJECT TO CONDITIONS
BEXOBRUTIDEG PHASE 3 TRIAL INITIATION PLANNED FOR SUMMER 2026 FOR SECOND-LINE CLL
Source text: ID:nGNE3BhSVf
Further company coverage: ROPC.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza